Ozempic maker Novo Nordisk (NVO) shared more details about its experimental anti-obesity pill — that seems to be more ...

Novo Nordisk's older weight-loss drug Saxenda helped children between the ages of 6 and under 12 reduce their body mass index ...

Novo Nordisk reported that its new obesity pill led to substantial weight loss in an early study, boosting the company’s ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

told the meeting that the promising results justify further research and a larger phase 2 trial is planned for the second half of this year, with results expected in around 2026. Novo Nordisk’s ...

Novo Nordisk said on Wednesday its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for ...

Novo Nordisk’s obesity drug Wegovy cut the risk ... presented Friday at the annual meeting of the European Society of Cardiology and published in the Lancet.

At the European Association for the Study of Diabetes annual meeting, Novo Nordisk A/S (NYSE:NVO) shared an abstract with data from the company’s next-generation weight loss candidate ...

Novo Nordisk A/S (NVO) has shared groundbreaking findings at the European Association for the Study of Diabetes meeting in Madrid ...

Novo Nordisk today announced the presentation of 21 abstracts (7 oral and 14 short oral presentations) at the upcoming 60th Annual Meeting of the European Association for the Study of diabetes ...

Novo Nordisk's experimental weight-loss pill, amycretin, demonstrated safety and tolerability in early-stage trials. The pill showed significant weight reduction, with patients losing up to 13.1% of ...

Amid an ongoing debate over what role, if any, GLP-1 medications should play in treating children who are still in elementary ...